Innovent Reveals Addition of Seven Innovative Medications, Including New Indication for TYVYT and SYCUME, to China's National Reimbursement Drug List | Intellectia.AI
Innovent Reveals Addition of Seven Innovative Medications, Including New Indication for TYVYT and SYCUME, to China's National Reimbursement Drug List
Written by Emily J. Thompson, Senior Investment Analyst
Innovent's NRDL Inclusion: Innovent Biologics announced that seven of its innovative products, including TYVYT® and SYCUME®, have been included in China's updated National Reimbursement Drug List (NRDL), effective January 1, 2026, enhancing patient access to critical therapies for various diseases.
New Indications and Treatments: The updated NRDL features new indications for TYVYT® in advanced endometrial cancer and SYCUME® for moderate-to-severe thyroid eye disease, addressing significant treatment gaps in these areas.
Innovative Therapies for Cancer: Other newly included therapies in the NRDL include Limertinib for NSCLC with specific mutations, Dupert® for KRAS G12C mutation, DOVBLERON® for ROS1-positive NSCLC, and Retsevmo® for cancers with RET alterations, providing targeted treatment options.
Commitment to Patient Accessibility: Innovent emphasizes its mission to empower patients with affordable, high-quality biopharmaceuticals, continuing to invest in innovative treatments across oncology, cardiovascular, autoimmune, and ophthalmology sectors to improve drug affordability and accessibility.
Wall Street analysts forecast NUVB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVB is 11.38 USD with a low forecast of 8.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast NUVB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVB is 11.38 USD with a low forecast of 8.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.910
Low
8.00
Averages
11.38
High
18.00
Current: 5.910
Low
8.00
Averages
11.38
High
18.00
RBC Capital
Leonid Timashev
Outperform
maintain
$9 -> $12
2026-01-21
New
Reason
RBC Capital
Leonid Timashev
Price Target
$9 -> $12
AI Analysis
2026-01-21
New
maintain
Outperform
Reason
RBC Capital analyst Leonid Timashev raised the firm's price target on Nuvation Bio to $12 from $9 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.
UBS
Michael Yee
Neutral
initiated
$10
2026-01-07
Reason
UBS
Michael Yee
Price Target
$10
2026-01-07
initiated
Neutral
Reason
UBS analyst Michael Yee initiated coverage of Nuvation Bio (NUVB) with a Neutral rating and $10 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NUVB
Unlock Now
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$10 -> $18
2025-12-11
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10 -> $18
2025-12-11
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Nuvation Bio to $18 from $10 and keeps a Buy rating on the shares. The firm cites its revised Ibtrozi revenue forecasts for the target increase.
Clear Street
Buy
maintain
$12
2025-11-26
Reason
Clear Street
Price Target
$12
2025-11-26
maintain
Buy
Reason
Clear Street reiterates a Buy rating and $12 price target on shares of Nuvation Bio after the company announced that it has discontinued development of NUV-1511, its lead DDC for advanced solid tumors. Clear Street does not view this as thesis-changing, telling investors in a research note that taletrectinib and safusidenib are distinct assets and that it expects blockbuster potential from taletrectinib and safusidenib's success, with pivotal trial completion in 2029, offers incremental upside to the firm's model.
About NUVB
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
